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Quinoxaline derivatives were studied as inhibitors of c-Met kinase, a receptor associated with high tumor grade and poor prognosis
in a number of human cancers. In this paper we used docking methodologies to predict the binding conformation of a set of
quinoxalines and to explain the differences of biological activities previously reported.
1. Introduction
Quinoxalines and quinoxalinones are attractive chemical
candidates in medicinal chemistry due to their capacity to
generate biological responses in their interaction with several
biological targets. They show antiviral [1], herbicidal [2], and
anti-inflammatory action [3].
Recent investigations revealed the pharmacological
potential of quinoxalines as anticancer agents [4], and
numerous theoretical studies were performed on quinoxaline
and its derivatives, in order to find new antineoplastic
compounds. Only a small number of them were based on
molecular docking analyses, considering promising cancer
targets from which structural information of the receptor is
available. One example is the molecular docking of quinox-
alines against human dihydrofolate reductase (hDHFR)
performed by Corona and coworkers [5], with the aim of
predicting the binding mode of quinoxalines in hDHFR.
They used AutoDock 3.05 docking program, and the protein
structure was taken from the crystal structure of the ternary
complex hDHFR-NADPH-methotrexate [5].
Another recent investigation pointed out the quinoxaline
scaffold as a template to the design of inhibitors of c-Met
kinase [6]. This tyrosine kinase receptor is known to be
deregulated and associated with high tumor grade and poor
prognosis in a number of human cancers. In the course
of one high throughput screening campaign, Porter and
collaborators selected one quinoxaline derivative as the most
promising structure to inhibit selectively the ATP binding
site of c-Met (IC50 = 1.3μM in the c-Met biochemical
assay) [6]. After that, they successfully optimized the activity
of the original structure by preparing and testing a set
of quinoxalines. Another important contribution from this
investigation was the X-ray crystal structure of the c-Met
with one of the new inhibitors synthesized (pdb code 3F66
[7]).
Following Porter’s research, we decided to contribute in
the analysis of the interaction of quinoxalines with c-Met
kinase. To this end, we used docking to predict the binding
conformation of the entire set of inhibitors (Figure 1) and
provided a rational explanation of the differences of activity
in terms of the differences of the interaction with the receptor
for the quinoxalines from which X-ray structures are not
available.
2. Materials and Methods
2.1. Biological Data. The IC50 values for inhibitors of c-Met,
that is, the concentration (μM) of inhibitor that produces
50% inhibition of c-Met, were taken from the literature [6].
The reported biological evaluation was carried out with an
IMAP time resolved fluorescence resonance energy transfer
(TR-FRET) assay. Accordingly, the pIC50(−log [IC50]) are
reported in Table 1.
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Figure 1: Compounds selected for the docking analysis.
ISRN Physical Chemistry 3
Table 1: Biological data and docking results for quinoxaline derivatives.
Compound c-Met IC50
(μM)
pIC50 da (A˚)
Binding energy
(Kcal/mol)
Compound c-Met IC50
(μM)
pIC50 da (A˚)
Binding energy
(Kcal/mol)
1 1.3 5.886 1.80 −11.6 18 0.8 6.097 1.93 −11.9
2 0% @ 100 <4 1.92 −10.5 19 12.9 4.889 2.24 −10.5
3 20.1 4.697 1.85 −10.5 20 2.0 5.699 2.08 −11.5
4 5.3 5.276 1.78 −11.3 21 0.39 6.409 2.09 −12.0
5 0% @ 100 <4 2.18 −10.5 22 0.17 6.770 1.94 −12.0
6 1.3 5.886 1.86 −11.7 23 0.33 6.481 1.92 −12.2
7 19.6 4.708 2.34 −10.7 24 1.9 5.721 1.94 −11.7
8 28.3 4.548 2.03 −10.6 25 1.1 5.959 2.07 −11.7
9 3.9 5.409 1.98 −11.2 26 7.1 5.149 2.78 −11.4
10 2.8 5.553 1.94 −11.4 27 0.035 7.456 1.86 −12.4
11 5.0 5.301 1.86 −11.4 28 0.54 6.268 2.02 −11.9
12 60.2 4.220 3.20 −10.7 29 0.055 7.260 1.97 −12.0
13 1.5 5.824 2.19 −11.2 30 0.32 6.495 2.03 −11.8
14 1.8 5.745 2.05 −11.6 31 0.017 7.770 1.96 −13.0
15 0% @ 100 <4 3.33 −10.9 32 0.73 6.137 1.94 −11.4
16 5.0 5.301 3.35 −11.1 33 0.031 7.509 2.02 −12.4
17 0.9 6.046 2.09 −11.4 34 0.38 6.420 2.13 −12.1
a
Distances derived from docking between the endocyclic N atom located at the positions 4 of the quinoxalines and the H atom of the MET1160.
2.2. Docking. We used the automated docking program
AutoDock 4.0 [8] to analyze the binding mode of the com-
pound of the set and AutoDockTools 1.5.2 related software
to prepare the inputs and analyze the results. The c-Met
receptor was prepared from the 1.4 A˚ resolution crystal
deposited by Porter et al. (pdb code 3F66) [6]. The crystal-
lographic water molecules, the original ligand (compound
17, Figure 1), and the γ-butyrolactone crystallized from the
buffer solution were stripped. Hydrogen atoms were added
using the leap module of AMBER10 [9].
We used AutoDock force field [10, 11] and the default
AutoDock parameters for all the variables. Gasteiger charges
were calculated for the ligands and the receptor. Quinoxa-
lines were docked considering two different possible proto-
nation states: the neutral structure and one monoprotonated
form (obtained by adding a hydrogen atom to the N4 of the
molecules). In this way we explored the possibility of binding
with protonated structures.
The ligands were docked using the Lamarckian Genetic
Algorithm (LGA) in the active site region. This region was
defined through a grid map with 60, 60, and 60 grid points
(X , Y , Z dimensions, resp.) that completely covers the space
initially occupied by the crystallographic ligand (coordinates:
X = −0.013, Y = −23.028, Z = 28.19). We use the
default grid spacing (0.375 angstroms) and achieved 100
docking runs considering the quinoxalines as flexible, that
is, all nonring torsions were considered active. The active
site was considered as a rigid molecule for all the residues
but MET1229 and TYR1230. It has been shown that these
residues have different conformations in several crystal struc-
tures (cf., e.g., the pdb crystal structure of 1ROP and 3F66),
and these conformational changes have been considered in
this investigation through flexible docking.
3. Results and Discussion
Table 1 shows the binding energies predicted by the Au-
toDock in conjunction with the biological data compiled
from the literature. We report here the results obtained
for the neutral form of quinoxalines, since no good results
were found with the protonated form: the predicted binding
energies were higher than those obtained from the neutral
structures and they did not correlate with the experimental
data.
A different situation was found with the neutral quinox-
alines: AutoDock is capable of predicting the active confor-
mation of compound 17, with RMS fit error of 0.158 relative
to the crystallographic structures. Figure 2 shows the docked
conformation of 17 in the active site. The binding reproduces
the X-ray determined interaction between the N-4 atom of
the quinoxaline ring andMet1160 of the kinase. These results
increase our confidence in the predicted binding disposition
of the other compounds, from which structural data is
not experimentally available. Binding energies predicted
by docking evidence an acceptable correlation with the
biological data (Figure 3), that is, themost active compounds
are those with more negative binding energy. The binding
modes obtained by docking for the quinoxalines resemble the
binding conformation determined for 17 by crystal structure
data: the aromatic 8-substituent is placed near the aromatic
group of TYR1230 residue; the group is placed at the position
2 (generally the piperazine scalffold) points outside the
cavity and is exposed to the solvent (Figure 4). Additionally,
there are H bond interactions comprising the endocyclic N
atom located at the position 4 of the backbone and one H
atom of the MET1160. The distances between these 2 atoms
are given in Table 1 for each molecule. The importance of
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Figure 2: Superposition of the docking conformation (in white)
and the crystallographic ligand (in orange) in the active site.
Hydrogen atoms were omitted for simplicity.
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Figure 3: Correlation between the free energy of binding and
biological data, expressed as pIC50 (r2 = 0.865).
this H-bonding interaction could be evidenced in the poor
results found for the docking simulations for the protonated
quinoxalines. In these structures, the H-binding was abol-
ished and the results of docking were not satisfactory. In
addition, we have to keep in mind the limitations of the
calculations performed here. AutoDock force field estimates
the desolvation potential based on the volume of atoms that
surround a given atom and shelter it from solvent, so it does
not consider the solvent explicitly [11]. This approximation
might also be the cause of poor results in case of protonated
ligands.
According to the data collected in Table 1, the inhibitory
activity was improved by the inclusion of groups containing
halogens at the position 6 of the quinoxaline skeleton
since compound 8 is less active than compounds 1, 9, and
10. Docking conformations predict this increase through
the better binding energy values, mainly caused by the
positive interactions between halogens and the hydrophobic
pocket placed in the active site, composed by lipophilic
residues as VAL1092, LEU1140, LEU1157, and ALA1226
(Figure 4). This interaction was also observed in the binding
conformation found for compound 11, which presents a
Figure 4: Docking solutions of the compounds 1 (carbon atoms in
yellow), 9 (carbon atoms in orange), and 10 (carbon atoms in pink).
Important residues of the active site of the kinase were highlighted
(in green). Color code for heteroatoms is as follows: fluorine: cyan,
nitrogen: blue, sulfur: yellow, oxygen: red, and chlorine: grey. Only
one hydrogen atom of MET1160 was shown for simplicity. H-
bonding interactions between the molecules and this residue were
shown as a dashed line. Distance values are given in Table 1.
methyl substituent, but not for compound 12 that has a polar
cyan group at the 6 positions.
In order to maximize the π-interactions with the TYR-
1230, Porter et al. incorporated one larger link between
the quinoxaline scaffold and the phenyl group (compounds
24–32, Figure 1) [6]. The best inhibitors obtained after
this modification present a two-atom N-linking chain, with
a 3-nitrosubstituent in the aromatic ring (compounds 27
and 31). Docking predicts the parallel-displaced stacking
arrangement between the aromatic ring of TYR1230 and the
phenyl substituent of compounds 27 and 31 (Figure 5).
In agreement with other authors [6], we believe that the
presence of the nitrogroup enhances the π-stacking interac-
tion for the compounds by means of its electron-withdraw-
ing effect. Additionally, we consider that the presence of the
nitrogroup in metaposition is optimal for the interaction
with ASP1222 through a hydrogen bond (Figure 5). The
replacement of the amino methyl linker by sulfonamide
group increases the activity (compound 31), possibly due to
the capacity of sulfonyl group to interact with hydrophobic
groups (Figure 5).
4. Conclusions
Docking techniques attempt to simulate the protein-ligand
recognition through molecular modeling tools in a rea-
sonable computation time. This objective represents a very
ambitious task due to the complexity of the system: we
need to simulate the interaction forces acting on the ligand
and the receptor for each possible conformation of the two
molecules, which means the consideration of hundred of
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Figure 5: Top view of the active site of the kinase with the docking
solutions for compounds 27 (carbon atoms in orange) and 31
(carbon atoms in pink). Distances between O atoms of the ligands
and N atom of ASP1222 were measured for both compounds.
Color code for heteroatoms is as follows: fluorine: cyan, nitrogen:
blue, sulfur: yellow, and oxygen: red. Only one hydrogen atom of
MET1160 was shown for simplicity.
thousands of degrees of freedom to explore the conforma-
tional space. For that reason these methodologies make sim-
plifying assumptions to allow for reasonable computation
time (such as restraining the movement of the protein and
simplifying the mathematical expression of the forces acting
on the complex), and these assumptions can lead to unusable
results. Consequently, the results obtained through docking
methodologies have to be considered keeping in mind these
limitations.
Here, we report the results of applying one docking
protocol to a set of quinoxalines and c-Met kinase in order to
analyze the difference of activity. Although the analysis has to
be considered preliminary, it has helped us to understand the
trend in the inhibitory activity of this set. The docking results
corroborate the experimental conformation found for one of
the ligands (compound 17), correlate with the IC50 data, and
allow us to analyze the importance of specific interaction for
describing the affinity of different quinoxaline derivatives.
These results can be considered only valid for the studied
series, but for this case we provide a simple and useful tool to
explain the interactions between the possible inhibitors and
the receptor when the crystal structures of the complex are
not available.
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